LAWLIS V BRYAN 4
4 · BIOMARIN PHARMACEUTICAL INC · Filed Apr 4, 2023
Insider Transaction Report
Form 4
LAWLIS V BRYAN
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2023-04-03−8,500→ 0 totalExercise: $67.81From: 2013-11-15Exp: 2023-05-14→ Common Stock (8,500 underlying) - Exercise/Conversion
Common Stock
2023-04-03$67.81/sh+8,500$576,385→ 37,450 total - Sale
Common Stock
2023-04-03$97.09/sh−8,500$825,265→ 28,950 total
Footnotes (2)
- [F1]Trade made pursuant to a 10b5-1 plan executed on August 29, 2022.
- [F2]Reflects the number of options outstanding after the transactions from this specific stock option grant.